Assembly Biosciences (NASDAQ:ASMB) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of Assembly Biosciences (NASDAQ:ASMB) from a buy rating to a hold rating in a report published on Monday.

Separately, HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a research report on Monday.

Assembly Biosciences Stock Performance

Shares of ASMB stock opened at $11.12 on Monday. The firm’s 50 day moving average price is $12.84 and its two-hundred day moving average price is $15.09. The stock has a market cap of $70.68 million, a PE ratio of -1.65 and a beta of 0.62. Assembly Biosciences has a 52-week low of $10.27 and a 52-week high of $19.93.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.75) by $0.18. The business had revenue of $7.36 million for the quarter, compared to analyst estimates of $7.05 million. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. As a group, sell-side analysts predict that Assembly Biosciences will post -6.87 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Michael Houghton acquired 3,202 shares of the stock in a transaction that occurred on Monday, December 30th. The stock was acquired at an average price of $15.61 per share, for a total transaction of $49,983.22. Following the transaction, the director now directly owns 3,202 shares in the company, valued at approximately $49,983.22. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ASMB. JPMorgan Chase & Co. raised its position in shares of Assembly Biosciences by 5,137.3% during the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 3,442 shares during the period. Palumbo Wealth Management LLC bought a new stake in Assembly Biosciences during the 4th quarter worth approximately $180,000. Marshall Wace LLP raised its holdings in Assembly Biosciences by 16.5% during the 4th quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 2,098 shares during the period. FMR LLC lifted its stake in Assembly Biosciences by 29.7% in the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 3,635 shares in the last quarter. Finally, Man Group plc acquired a new position in shares of Assembly Biosciences in the fourth quarter valued at approximately $309,000. 19.92% of the stock is owned by institutional investors and hedge funds.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.